Jiangsu Lianhuan Pharmaceutical Co., Ltd. (SHA:600513)
12.49
-0.44 (-3.40%)
Nov 13, 2026, 3:00 PM CST
SHA:600513 Revenue
Jiangsu Lianhuan Pharmaceutical had revenue of 757.34M CNY in the quarter ending September 30, 2026, a decrease of -4.99%. This brings the company's total for the last twelve months to 2.96B, up 13.82% year-over-year. In the year 2025, Jiangsu Lianhuan Pharmaceutical had annual revenue of 2.71B with 25.52% growth. That makes Jiangsu Lianhuan Pharmaceutical the 11,959th largest company in the world by revenue and 2,055th in China.
Revenue (ttm)
2.96B
Revenue Growth
+13.82%
P/S Ratio
1.22
Revenue / Employee
1.39M
Employees
2,131
Market Cap
3.57B
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full SHA:600513 breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.71B | 551.40M | 25.52% |
| Dec 31, 2024 | 2.16B | -13.64M | -0.63% |
| Dec 31, 2023 | 2.17B | 218.94M | 11.20% |
| Dec 31, 2022 | 1.96B | 309.34M | 18.80% |
| Dec 31, 2021 | 1.65B | 259.78M | 18.74% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Zhejiang Starry Pharmaceutical | 2.61B |
| Henan Taloph Pharmaceutical Stock Co.,Ltd | 1.70B |
| Nanjing Well Pharmaceutical Group | 1.40B |
| Qianjiang Yongan Pharmaceutical | 1.15B |
| Tibet Weixinkang Medicine | 1.09B |
| LanZhou Foci Pharmaceutical | 941.70M |
| Nanjing Hicin Pharmaceutical | 814.80M |
| Shanghai Xiao Fang Pharmaceutical | 553.96M |